Dopamine agonists and risk: impulse control disorders in Parkinson's disease.

Dopamine agonists and risk: impulse control disorders in Parkinson's disease.

Show other versions (1)

Impulse control disorders are common in Parkinson's disease, occurring in 13.6% of patients. Using a pharmacological manipulation and a novel risk taking task while performing functional magnetic resonance imaging, we investigated the relationship between dopamine agonists and risk taking in pa...

Full description

Bibliographic Details
Main Authors:	Voon, V, Gao, J, Brezing, C, Symmonds, M, Ekanayake, V, Fernandez, H, Dolan, R, Hallett, M
Format:	Journal article
Language:	English
Published:	2011

Similar Items

Dopamine agonists and risk: Impulse control disorders in Parkinson's; Disease
by: Voon, V, et al.
Published: (2011)

Impulse control disorders in Parkinson's disease: recent advances.
by: Voon, V, et al.
Published: (2011)

Impulse control disorders and dopamine agonists
by: D. Martins, et al.
Published: (2021-04-01)

Impulse control and related behavioral disorders (ICRD) in Idiopathic Parkinson’s Disease treated with different dopamine agonists in Hong Kong: Is any dopamine agonist better?
by: Hiu Fung Wu, et al.
Published: (2024-01-01)

An update on impulse control disorders in Parkinson's disease
by: Voon, V, et al.
Published: (2012)

Dopamine and reward hypersensitivity in Parkinson's disease with impulse control disorder
by: Drew, DS, et al.
Published: (2020)

Progress in the treatment with dopamine receptor agonist-induced impulse control disorders
by: ZHANG Rui, WU Xue-yan
Published: (2022-09-01)

Dopamine Agonist Therapy in Advanced Parkinson’s Disease
by: Heinz Reichmann
Published: (2009-05-01)

Dopamine agonist monotherapy utilization in patients with Parkinson’s disease
by: Monica Frazer, et al.
Published: (2023-01-01)

The efficacy of the dopamine agonist Rotigotine in the treatment of Parkinson's disease
by: Marina Romanovna Nodel
Published: (2013-11-01)

Dopamine genetic risk score predicts impulse control behaviors in Parkinson’s disease
by: Alison Hall, et al.
Published: (2021-01-01)

Mythology of Parkinson’s disease: from levodopa phobia to dopamine agonist phobia
by: O. S. Levin, et al.
Published: (2020-12-01)

Parkinson's disease fatigability and its correction with the dopamine receptor agonist pramipexole
by: M. R. Nodel
Published: (2011-12-01)

Capacities of the dopamine receptor agonist pramipexole in the treatment of patients with Parkinson’s disease
by: S N Illarioshkin
Published: (2012-06-01)

Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study
by: Unrath Alexander, et al.
Published: (2009-06-01)

IMPULSIVE-COMPULSIVE DISORDERS IN PARKINSON'S DISEASE. CLINICAL CASES
by: N. V. Fedorova, et al.
Published: (2015-10-01)

Dopamine-induced changes to thalamic GABA concentration in impulsive Parkinson disease patients
by: Paula Trujillo, et al.
Published: (2022-04-01)

Impulse control disorders in Parkinson's disease
by: Shakya Bhattacharjee
Published: (2020-01-01)

Impulse control disorders in Parkinson's disease
by: An-mu XIE, et al.
Published: (2013-08-01)

Parkinson's Disease: Impulsivity Does Not Cause Impulse Control Disorders but Boosts Their Severity
by: Juan Marín-Lahoz, et al.
Published: (2018-09-01)

Impact of behavioral side effects on the management of Parkinson patients treated with dopamine agonists
by: Mohammad Edrees Mohammad, et al.
Published: (2021-01-01)

Impulse control and related disorders in Parkinson’s disease
by: Antonio Pedro Vargas, et al.

Editorial: Impulse Control Disorders, Impulsivity and Related Behaviors in Parkinson's Disease
by: Mayela Rodríguez-Violante, et al.
Published: (2019-09-01)

Dopamine agonist treatment increases sensitivity to gamble outcomes in the hippocampus in de novo Parkinson’s disease
by: Joyce P.M. van der Vegt, et al.
Published: (2020-01-01)

Dopamine D<sub>1</sub> Agonists: First Potential Treatment for Late-Stage Parkinson’s Disease
by: Mechelle M. Lewis, et al.
Published: (2023-05-01)

Cost-effectiveness of dopamine agonists and monoamine oxidase B inhibitors in Parkinson’s
by: McIntosh, E, et al.
Published: (2021)

Genetic prediction of impulse control disorders in Parkinson's disease
by: Daniel Weintraub, et al.
Published: (2022-07-01)

Motivational and myopic mechanisms underlying dopamine medication-induced impulsive-compulsive behaviors in Parkinson's disease
by: Andrew Dawson, et al.
Published: (2023-01-01)

Dopamine, Salience, and Response Set Shifting in Prefrontal Cortex.
by: Shiner, T, et al.
Published: (2014)

Depression and Impulsivity Self-Assessment Tools to Identify Dopamine Agonist Side Effects in Patients With Pituitary Adenomas
by: José Miguel Hinojosa-Amaya, et al.
Published: (2020-10-01)

A systematic review of impulse control disorders in Parkinson's disease.
by: Callesen, M, et al.
Published: (2013)

Evaluation of risk factors for impulse control disorder in Parkinson’s disease in northern China
by: Wenhua Ren, et al.
Published: (2023-11-01)

Study on the incidence and related risk factors for impulsive control disorders in Parkinson's disease
by: XIE Xin, et al.
Published: (2021-11-01)

Dopamine dysregulation syndrome in Parkinson’s disease
by: A V Nikitina, et al.
Published: (2013-03-01)

Impulsive-compulsive behaviour in early Parkinson’s disease is determined by apathy and dopamine receptor D3 polymorphism
by: Hendrik Theis, et al.
Published: (2023-11-01)

Dopamine Genetics: Substance Use Disorders vs. Parkinson’s Disease
by: Z. Carl Lin, et al.
Published: (2019-12-01)

The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
by: Xiaoshuang Liu, et al.
Published: (2019-01-01)

The effect of motivation on movement: a study of bradykinesia in Parkinson's disease
by: Shiner, T, et al.
Published: (2012)

Impulsivity and apathy in Parkinson's disease
by: Sinha, N, et al.
Published: (2013)

Impulse control disorders and related behaviours (ICD-RBs) in Parkinson′s disease patients: Assessment using “Questionnaire for impulsive-compulsive disorders in Parkinson′s disease” (QUIP)
by: Ashish Sharma, et al.
Published: (2015-01-01)